Eli Lilly and Company (NYSE: LLY) and Nexus Pharmaceuticals, LLC have announced a definitive agreement for Lilly to acquire a manufacturing facility from Nexus, a prominent sterile manufacturer in the…
Astellas Pharma Inc. has confirmed that the U.S. District Court for the District of Delaware has issued a Report and Recommendation advising against granting Astellas’ motion for a preliminary injunction.…
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reported today that it has received a notice from the NYSE American LLC, dated April 18, 2024, indicating that the Company is currently below…
Grifols, a global healthcare leader renowned for its plasma-derived medicines, commemorated the 50th anniversary of its Clayton, N.C. flagship facility today. Since its inception, this site has been pivotal in…
Shionogi & Co., Ltd. unveiled groundbreaking findings from the largest European real-world evidence study, PERSEUS, at the 34th ESCMID Global (formerly ECCMID) conference in Barcelona from April 27th to 30th,…
Bayer AG has entered into a long-term agreement with Wuppertaler Stadtwerke (WSW), the public utility company of Wuppertal in North Rhein-Westphalia, Germany, to procure electricity from renewable sources. This partnership…
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has announced that the U.S. Food and Drug Administration (FDA) has given approval for Alecensa® (alectinib), an anaplastic lymphoma kinase (ALK) inhibitor, to be…
GSK plc (LSE/NYSE: GSK) has unveiled encouraging outcomes from the pivotal EAGLE-1 phase III trial concerning gepotidacin, a prospective first-in-class oral antibiotic offering a novel approach to combat uncomplicated urogenital…
Australia’s Newest Biotech Incubator, Jumar Bioincubator, Opens with Ambitious Ventures Jumar Bioincubator has officially launched in Melbourne, welcoming its first cohort of 16 pioneering early-stage ventures. The event, graced by…
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has unveiled significant progress in its suzetrigine pain program, potentially introducing the first new class of medication for acute and neuropathic pain in over twenty…
Novartis has revealed findings from the ALITHIOS open-label extension study, demonstrating the sustained efficacy of continuous Kesimpta® (ofatumumab) treatment for up to six years in individuals recently diagnosed with relapsing…
Roche Receives FDA Approval for Alecensa as Adjuvant Therapy in ALK-Positive Early-Stage Lung Cancer Roche has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Alecensa®…